Despite the legalisation of medical cannabis in the UK, many patients continue to encounter significant barriers to access, often necessitating private care at substantial cost. The journey of Hannah Deacon and her son Alfie, as reported by GN: medical cannabis prescription, highlights the complexities families face in navigating the healthcare system to secure appropriate treatment.
Alfie’s Challenging Start and the Search for Relief
Alfie’s early life was marked by severe, whole-body seizures that began when he was just eight months old. Despite extensive medical intervention, including life support, doctors initially struggled to diagnose the cause. At age five, Alfie received a diagnosis of PCDH19, a rare form of epilepsy. Conventional anti-epileptic medications proved ineffective in controlling his seizures and significantly impacted his quality of life, leading to physical and mental developmental impairment.
Faced with limited options, Hannah Deacon began researching alternative approaches, discovering information online about the potential therapeutic properties of cannabis for epilepsy. At the time, medical cannabis was classified as a Schedule 1 substance in the UK, indicating no accepted medical value and imposing strict controls, even more so than for some other controlled substances.
A Historical Perspective on Cannabis in Medicine
The medical use of cannabis has a long history, as evidenced by the work of William O’Shaughnessy in the 19th century. O’Shaughnessy, a surgeon with the East India Company, conducted extensive studies on Indian hemp. His 1839 monograph detailed trials suggesting cannabis could address a range of human diseases, including “convulsion disorders” now known as epilepsy.
However, global drug control legislation, particularly the League of Nations’ Second Opium Convention in 1925, led to cannabis being included on a list of prohibited drugs. This shift, reinforced by domestic legislation like the UK’s 1928 Dangerous Drugs Act, gradually removed cannabis products from medical practice and led to its strict policing in the 20th century, often associated with moral panics rather than medical potential.
Navigating Modern Medical Cannabis Access
Hannah’s attempts to discuss cannabis with Alfie’s UK doctors were met with resistance. One doctor reportedly threatened to involve social services if she continued to inquire about cannabis as a treatment option. This experience underscores the cultural and institutional suspicion towards cannabinoid therapies that persisted within parts of the medical establishment.
Determined to find help, the family relocated to the Netherlands, where medical cannabis was a more mainstream treatment for neurological disorders. There, Alfie began a new treatment regimen involving medical cannabis, with doctors gradually adjusting the dosage of cannabidiol (CBD), a non-psychoactive compound found in the plant. Following the adjustment of his cannabidiol (CBD) dosage, reaching 150ml, Alfie experienced a remarkable 17 days without a single seizure, and his mother observed a significant improvement in his engagement with the world.
Upon returning to the UK, Alfie had achieved 40 days without a seizure, demonstrating the instrumental role medical cannabis appeared to play in stabilising his condition. This personal success spurred Hannah Deacon to campaign for changes to UK law, advocating for broader patient access to medical cannabis.
The Evolving Landscape of Prescribing Pathways
Today, the landscape for medical cannabis access in the UK has evolved, with over 30 private clinics now prescribing. These clinics offer pathways for patients seeking treatment for conditions such as chronic pain, sleep deprivation, and anxiety. However, the initial promise of widespread NHS access following legalisation has not fully materialised, leaving many patients to bear the substantial costs of private prescriptions.
The experience of families like the Deacons highlights the ongoing need for clearer, more accessible prescribing pathways within public health systems. While the legal framework for medical cannabis has shifted, the practicalities of patient access remain a critical area for development, ensuring that those who could benefit from cannabinoid therapies are not hindered by financial or systemic barriers.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
